Dr. Jason Efstathiou
Dr. Efstathiou holds a B.S. from Yale University, M.D. from Harvard Medical School (HMS), D.Phil. from the University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program. He serves as Associate Professor of Radiation Oncology at HMS and the Director of the Genitourinary Division in Radiation Oncology and Clinical Co-Director of The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic at the Massachusetts General Hospital (MGH). His clinical practice focuses on treatment of patients with prostate, bladder, testicular and other urologic cancers, as well as proton beam and brachytherapy. His research has informed clinical practice guidelines and focuses on the effectiveness of advanced/emerging therapies for prostate cancer, as well as the adverse effects of hormonal therapy, improving radiation therapy for testicular cancer, and long-term outcomes of bladder-sparing chemoradiation for bladder cancer. He is the recipient of significant grant funding and serves as Principal Investigator of multiple studies including a multi-center randomized phase III trial of IMRT versus proton beam for localized prostate cancer using patient-reported outcomes. His commitment to service/patient care has been recognized as honoree for the MGH Cancer Center’s “The One Hundred” and as nominee for the Brian A. McGovern Award for Clinical Excellence. He lectures nationally and internationally and holds leadership positions in Radiation Oncology including within the cooperative groups (Co-Chair, Clinical Effectiveness, NRG), professional societies (Chair, GU Scientific Track, ASTRO), and National Cancer Institute (Co-Chair, Bladder Cancer Task Force, NCI). Other projects of his include the development of web-based patient decision aids/support tools, evaluating the multidisciplinary approach to cancer care, and significant global oncology outreach efforts. Specifically, he serves on the Global Task Force on Radiotherapy for Cancer Control for the Union for International Cancer Control, the Dana-Farber/Harvard Cancer Center Global Oncology Steering Committee, and has co-founded and co-directs BOTSOGO (Botswana Oncology Global Outreach). BOTSOGO is a longitudinal collaborative partnership between MGH/Harvard and the resource-limited oncology community in Botswana, which has laid the foundation for educational, training, capacity building, and research initiatives.
Dr. Scott Dryden-Peterson
Dr. Dryden-Peterson is a clinician researcher at the Brigham and Women’s Hospital and the Botswana Harvard AIDS Institute. He received his undergraduate degree from Harvard College, an M.D. from Harvard Medical School, an M.Sc. in Epidemiology from the Harvard T.H. Chan School of Public Health, and completed his Internal Medicine and Infectious Disease training at the Brigham and Women’s Hospital and Massachusetts General Hospital. He has been involved in research and capacity development in Africa since 2002. His research focuses on cancers arising the context of HIV, which have become the leading cause of death for patients accessing antiretroviral therapy globally. His work has identified HIV-associated cancers as an important driver for the expanding burden of malignancies in Africa and the limited effect of HIV antiretroviral therapy to mitigate excess cancer risk. In Botswana, he leads one of the largest oncology cohorts of HIV-associated cancers globally and several ongoing interventional and observational studies. He is co-founder and co-director of the Botswana Oncology Global Outreach (BOTSOGO), co-director of the non-communicable disease scientific working group at the Harvard Center for AIDS Research, a member of the Executive Committee of the Botswana Harvard AIDS Institute, and serves on the Dana-Farber/Harvard Cancer Center Globally Oncology Steering Committee. Clinically, he attends as an infectious disease specialist for oncology and transplant patients at the Brigham and Women’s Hospital.